Tropocells USA Executive Director
Dr. Riggs has been using regenerative therapies in clinical practice for the past 6 years. His clinic in Portland, Oregon was the first in the U.S. to use Tropocells PRP.
“Tropocells is by far the best PRP kit on the U.S. market. It does not produce a painful inflammatory flare like other systems since it removes 100% of the RBCs and >90% of the neutrophils. Our patients have had very positive clinical outcomes with Tropocells. Its ease of use, consistent formulation, and superior cellular profile make Tropocells the PRP system of choice.”
Tropocells USA Chief Medical Officer - PRP Division
Dr. Riggs is a specialist in regenerative orthobiologics. He has researched and sampled many PRP systems and is passionate about the Tropocells PRP system because of its unique cell-separation technology and optimized formulation.
“No other system comes close to delivering such a strong anabolic profile. Tropocells PRP is an outstanding product. It’s competitively priced, easy to use, and it consistently provides quality clinical outcomes — thus making it exceptional for business, staff, and patients.”
Tropocells USA Chief Medical Officer - PRF Division
Dr. Crittenden is the Director of Clinical Research and Chief Medical Officer of the Platelet Rich Fibrin (PRF) division. He is a practicing Board Certified Oral and Maxillofacial Surgeon in Kansas. While receiving his undergraduate degree from Belmont University, he performed in research in cellular immunotherapy. As a doctoral student he conducted research projects in the pathogenesis of antibiotic-resistant oral microorganisms and their effects in advancement of oral disease.
Dr. Crittenden received his Doctor of Dental Medicine from the University of Kentucky and completed his residency at Cleveland Metro Health Medical Center, which is a level one trauma center and the regional burn center. Dr. Crittenden saw and treated many serious traumatic wounds and burns while on rotation at Cleveland Metro Health.
Shortly after completing his residency Dr. Crittenden became a clinical instructor for the Air Force Oral and Maxillofacial Surgery residency program and did a combat tour as a member of the Head and Neck Trauma team in Iraq. He has lectured on wounding mechanisms and the complexity of wound healing from ballistic and blast trauma as well as non-healing wounds that are produced from these injuries.
“I am committed to the research and development of a wound care system that can address closure of chronic, non-healing wounds. We are conducting clinical trials in the United States, as well as abroad, with Tropocells PRP and PRF in wound care. “Our proprietary cell separation process yields a formulation of PRF which has a unique biological signature with a high anabolic effect while limiting the initial catabolic effects of inflammation. This ratio of anabolism to catabolism allows for favorable cellular signaling and prolonged growth factor release which promotes closure of non-healing wounds. The superior cellular profile of Tropocells positions it as the next-generation regenerative treatment for chronic wounds such as diabetic foot ulcers and venous stasis ulcers.”
For more information, email us at firstname.lastname@example.org
FDA cleared 510(k) Class II medical device: Tropocells PRP is intended for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care. The PRP is mixed with autograft or allograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK110035